Onychomycosis

Onychomycosis
Classification and external resources

A toenail affected by Onychomycosis
ICD-10 B35.1
ICD-9 110.1
DiseasesDB 13125
MedlinePlus 001330
eMedicine derm/300
MeSH D014009

Onychomycosis (also known as "Dermatophytic onychomycosis,"[1] "Ringworm of the nail,"[1] and "Tinea unguium"[1]) means fungal infection of the nail.[2] It is the most common disease of the nails and constitutes about a half of all nail abnormalities.[3]

This condition may affect toenails or fingernails, but toenail infections are particularly common. The prevalence of onychomycosis is about 6-8% in the adult population.[4]

Contents

Symptoms

The nail plate can have a thickened, yellow, or cloudy appearance. The nails can become rough and crumbly, or can separate from the nail bed. There is usually no pain or other bodily symptoms, unless the disease is severe.[5]

Dermatophytids are fungus-free skin lesions that sometimes form as a result of a fungus infection in another part of the body. This could take the form of a rash or itch in an area of the body that is not infected with the fungus. Dermatophytids can be thought of as an allergic reaction to the fungus.

Patients with onychomycosis may experience significant psychosocial problems due to the appearance of the nail. This is particularly increased when fingernails are affected.[6]

Causes

Parts of a nail

The causative pathogens of onychomycosis include dermatophytes, Candida, and non-dermatophytic molds. Dermatophytes are the fungi most commonly responsible for onychomycosis in the temperate western countries; meanwhile, Candida and non-dermatophytic moulds are more frequently involved in the tropics and subtropics with a hot and humid climate.[7]

Dermatophytes

Trichophyton rubrum is the most common dermatophyte involved in onychomycosis. Other dermatophytes that may be involved are Trichophyton interdigitale, Epidermophyton floccosum, Trichophyton violaceum, Microsporum gypseum, Trichophyton tonsurans, Trichophyton soudanense (considered by some to be an African variant of T. rubrum rather than a full-fledged separate species) and the cattle ringworm fungus Trichophyton verrucosum. A common outdated name that may still be reported by medical laboratories is Trichophyton mentagrophytes for T. interdigitale. The name T. mentagrophytes is now restricted to the agent of favus skin infection of the mouse; though this fungus may be transmitted from mice and their danders to humans, it generally infects skin and not nails.

Other

Other causative pathogens include Candida and non-dermatophytic moulds, in particular members of the mould generation Scytalidium (name recently changed to Neoscytalidium), Scopulariopsis, and Aspergillus. Candida mainly cause fingernail onychomycosis in people whose hands are often submerged in water. Scytalidium mainly affects people in the tropics, though it persists if they later move to areas of temperate climate.

Other molds more commonly affect people older than 60 years, and their presence in the nail reflects a slight weakening in the nail's ability to defend itself against fungal invasion.

Types

There are four classic types of onychomycosis:[8]:305

Distal subungual onychomycosis
The most common form of tinea unguium usually caused by Trichophyton rubrum, which invades the nail bed and the underside of the nail plate.
White superficial onychomycosis
Caused by fungal invasion of the superficial layers of the nail plate to form "white islands" on the plate. Accounts for only 10 percent of onychomycosis cases.
Proximal subungual onychomycosis
Fungal penetration of the newly formed nail plate through the proximal nail fold. It is the least common form of tinea unguium in healthy people but found more commonly when the patient is immunocompromised.
Candidal onychomycosis
Candida species invade fingernails usually occurring in persons who frequently immerse their hands in water. This normally requires the prior damage of the nail by infection or trauma.

Diagnosis

To avoid misdiagnosis as nail psoriasis, lichen planus, contact dermatitis, trauma, nail bed tumor or yellow nail syndrome, laboratory confirmation may be necessary. The three main approaches are potassium hydroxide smear, culture and histology. This involves microscopic examination and culture of nail scrapings or clippings. Recent results indicate that the most sensitive diagnostic approaches are direct smear combined with histological examination,[9] and nail plate biopsy using periodic acid-Schiff stain.[10] To reliably identify nondermatophyte moulds several samples may be necessary.[11]

Treatment

Onychomycosis due to Trychophyton rubrum, right and left great toe.

Treatment of onychomycosis is challenging because the infection is embedded within the nail and is difficult to reach. As a result full removal of symptoms is very slow and may take a year or more.

Pharmacological

Most treatments are either systemic antifungal medications such as terbinafine and itraconazole, or topical such as nail paints containing ciclopirox or amorolfine. There is also evidence for combining systemic and topical treatments.[12]

For superficial white onychomycosis systemic rather than topical antifungal therapy is advised.[13]

Relative effectiveness of treatments

In July 2007 a meta-study reported on clinical trials for topical treatments of fungal nail infections. The study included 6 randomised controlled trials dating up to March 2005.[14] The main findings are:

A 2002 study compared the efficacy and safety of terbinafine in comparison with placebo, itraconazole and griseofulvin in treating fungal infections of the nails.[15] The main findings were that for reduced fungus terbinafine was found to be significantly better than itraconazole and griseofulvin, and terbinafine was better tolerated than itraconazole.

Drug pipeline

Most drug development activities are focused on

Active clinical trials investigating Onychomycosis:[19]

Phase III

Phase II

Drug-free treatments

Newer treatments include use of laser light sources which kill the fungus in the nail bed. A Noveon-type laser that is already in use by physicians for some types of cataract surgery has proved very effective and painless.

A promising new laser treatment for toenail fungus has been cleared by the Food and Drug Administration for the PinPointe FootLaser system, which has been available in the U.S. since September 2008.[32]

Natural remedies

As with many diseases, there are also some scientifically unverified folk or alternative medicine remedies.

Risk factors

Risk factors for onychomycosis include family history, increasing age, poor health, prior trauma, warm climate, participation in fitness activities, immunosuppression (eg, HIV, drug induced), communal bathing, and occlusive footwear.

See also

References

  1. 1.0 1.1 1.2 Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. pp. 1135. ISBN 1-4160-2999-0. 
  2. onychomycosis at Dorland's Medical Dictionary
  3. Szepietowski JC, Salomon J (2007). "Do fungi play a role in psoriatic nails?". Mycoses 50 (6): 437–42. doi:10.1111/j.1439-0507.2007.01405.x. PMID 17944702. 
  4. "Impact 07 - Dermatology" (PDF). Bay Bio. 2007. http://www.baybio.org/pdf/IMPACT07_Derm.pdf. Retrieved 2007-06-13. 
  5. Onychomycosis at eMedicine
  6. Szepietowski JC, Reich A (September 2008). "Stigmatisation in onychomycosis patients: a population-based study". Mycoses 52: 343. doi:10.1111/j.1439-0507.2008.01618.x. PMID 18793262. 
  7. Chi CC, Wang SH, Chou MC (2005). "The causative pathogens of onychomycosis in southern Taiwan". Mycoses 48 (6): 413–20. doi:10.1111/j.1439-0507.2005.01152.x. PMID 16262878. 
  8. James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0. 
  9. Karimzadegan-Nia M; Mir-Amin-Mohammadi A; Bouzari N, Firooz A (2007). "Comparison of direct smear, culture and histology for the diagnosis of onychomycosis". Australas. J. Dermatol. 48 (1): 18–21. doi:10.1111/j.1440-0960.2007.00320.x. PMID 17222296. 
  10. Weinberg JM; Koestenblatt EK; Tutrone WD; Tishler HR; Najarian L (2003). "Comparison of diagnostic methods in the evaluation of onychomycosis". J. Am. Acad. Dermatol. 49 (2): 193–7. doi:10.1067/S0190-9622(03)01480-4. PMID 12894064. 
  11. PubMed
  12. Rodgers P, Bassler M (2001). "Treating onychomycosis". Am Fam Physician 63 (4): 663–72, 677–8. PMID 11237081. http://www.aafp.org/afp/20010215/663.html. 
  13. Baran R, Faergemann J, Hay RJ (2007). "Superficial white onychomycosis--a syndrome with different fungal causes and paths of infection". J. Am. Acad. Dermatol. 57 (5): 879–82. doi:10.1016/j.jaad.2007.05.026. PMID 17610995. 
  14. Crawford F, Hollis S (2007). "Topical treatments for fungal infections of the skin and nails of the foot". Cochrane Database Syst Rev (3): CD001434. doi:10.1002/14651858.CD001434.pub2. PMID 17636672. 
  15. Haugh M, Helou S, Boissel JP, Cribier BJ (2002). "Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials". Br. J. Dermatol. 147 (1): 118–21. doi:10.1046/j.1365-2133.2002.04825.x. PMID 12100193. 
  16. Mitchel L. Zoler (April 1, 2004). "Boosts drug entry into nails: urea, ciclopirox combo tested for onychomycosis.(Focus on Skin Disorders)". Internal Medical News. pp. 69. 
  17. Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A (2007). "The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis". The Journal of dermatological treatment 18 (1): 46–52. doi:10.1080/09546630600965004. PMID 17373090. 
  18. Baran R, Sigurgeirsson B, Berker DD, et al. (2007). "A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement". British Journal of Dermatology 157 (1): 149. doi:10.1111/j.1365-2133.2007.07974.x. PMID 17553051. 
  19. clinicaltrials.gov
  20. ClinicalTrials.gov NCT00459537
  21. http://www.fiercebiotech.com/press-releases/nexmed-announces-decision-nm100060
  22. NEXMED Medicines of the Future
  23. ClinicalTrials.gov NCT00356915
  24. ClinicalTrials.gov NCT00443820 and ClinicalTrials.gov NCT00443898
  25. ClinicalTrials.gov NCT00935649 and ClinicalTrials.gov NCT00776464
  26. ClinicalTrials.gov NCT01008033
  27. ClinicalTrials.gov NCT00781820
  28. Barak O, Loo DS (2007). "AN-2690, a novel antifungal for the topical treatment of onychomycosis". Curr Opin Investig Drugs 8 (8): 662–8. PMID 17668368. 
  29. ClinicalTrials.gov NCT00491764
  30. ClinicalTrials.gov NCT00356915
  31. NanoBio - Onychomycosis
  32. Cathy Becker, Jonann Brady (April 9, 2009). "Promising New Treatment for Fungus-Free Feet". ABC news. http://abcnews.go.com/Health/OnCall/story?id=7113863&page=1. Retrieved 2009-11-06. 
  33. Buck DS, Nidorf DM, Addino JG (1994). "Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole". J Fam Pract 38 (6): 601–5. PMID 8195735. 
  34. Nenoff P, Haustein UF, Brandt W (1996). "Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro". Skin Pharmacol. 9 (6): 388–94. doi:10.1159/000211450. PMID 9055360. 
  35. "Tea tree oil (Melaleuca alternifolia)". Drugs & Supplements. Mayo Clinic. May 1, 2006. http://www.mayoclinic.com/health/tea-tree-oil/NS_patient-teatreeoil#31C383D1-E7FF-0DBD-1B59A74BE7EB5F8D. Retrieved 2008-01-29. 
  36. von Woedtke T, Schlüter B, Pflegel P, Lindequist U, Jülich WD (1999). "Aspects of the antimicrobial efficacy of grapefruit seed extract and its relation to preservative substances contained". Pharmazie 54 (6): 452–6. PMID 10399191. 
  37. Sakamoto S, Sato K, Maitani T, Yamada T (1996). "[Analysis of components in natural food additive "grapefruit seed extract" by HPLC and LC/MS]" (in Japanese). Eisei Shikenjo hōkoku. Bulletin of National Institute of Hygienic Sciences (114): 38–42. PMID 9037863. 
  38. Takeoka G, Dao L, Wong RY, Lundin R, Mahoney N (2001). "Identification of benzethonium chloride in commercial grapefruit seed extracts". J. Agric. Food Chem. 49 (7): 3316–20. doi:10.1021/jf010222w. PMID 11453769. 
  39. Takeoka GR, Dao LT, Wong RY, Harden LA (2005). "Identification of benzalkonium chloride in commercial grapefruit seed extracts". J. Agric. Food Chem. 53 (19): 7630–6. doi:10.1021/jf0514064. PMID 16159196. 
  40. Ganzera M, Aberham A, Stuppner H (2006). "Development and validation of an HPLC/UV/MS method for simultaneous determination of 18 preservatives in grapefruit seed extract". J. Agric. Food Chem. 54 (11): 3768–72. doi:10.1021/jf060543d. PMID 16719494. 
  41. Ramsewak RS, et al. In vitro antagonistic activity of monoterpenes and their mixtures against 'toe nail fungus' pathogens. Phytother Res. 2003 Apr;17(4):376-9.
  42. PMID 19683043
  43. PMID 18671197